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bjectives The aim of this study was to explore the determinants of neointimal coverage after
irolimus-eluting stent (SES).
ackground Although SES has signiﬁcantly reduced in-stent restenosis by inhibiting neointimal hy-
erplasia, insufﬁcient neointimal coverage after stenting might result in adverse outcomes.
ethods We evaluated 28 SES lesions with both angioscopy and intravascular ultrasound (IVUS).
uantitative assessments of the lesions and stent expansion were performed by IVUS at the time of
tent implantation, and degree of neointimal coverage was judged by angioscopy at follow-up
11  6 months) whether the stent struts were embedded by the neointima (“complete/incomplete”
eointimal coverage).
esults “Complete” coverage was identiﬁed in 10 (36%), and “incomplete” coverage was identiﬁed
n 18 (64%). Time from the stenting to angioscopy as well as the lesion and procedural characteris-
ics were similar between the complete and incomplete coverage groups. The IVUS parameters were
lso similar, except for the ﬁnal minimum stent cross-sectional area (CSA) (7.0  1.8 mm2 in com-
lete vs. 5.3  1.9 mm2 in incomplete, p  0.02) and lumen CSA at the distal reference site (6.1 
.4 mm2 in complete vs. 4.9  1.2 mm2 in incomplete, p  0.02). The ratio of the stent area to the
essel area was signiﬁcantly larger in the complete coverage than in the incomplete coverage group
0.52  0.11 vs. 0.39  0.09, p  0.002).
onclusions Adequate stent sizing relative to the vessel size might contribute to the angioscopi-
ally complete neointimal coverage after SES implantation. (J Am Coll Cardiol Intv 2009;2:989–94)
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990rug-eluting stents (DES) have significantly reduced in-
tent restenosis by inhibiting neointimal hyperplasia com-
ared with bare-metal stents (BMS) (1,2). Conversely,
oncerns have been raised regarding possible increase in late
tent thrombosis and death compared with BMS (3–7).
echanisms of stent thrombosis remain unclear, although
everal pathological and clinical investigations have dis-
losed the potential mechanisms of stent thrombosis (8–17).
tent thrombosis might occur through the mechanisms of
rocedural-related factors, inadequate healing processes,
See page 995
nd lack of neointima and/or re-endothelialization, similar
o those after vascular brachytherapy (18 –20). Although
ntravascular ultrasound (IVUS) is a useful device, by
uantitatively measuring the degree of stent expansion as
ell as vessel diameters and areas, IVUS resolution is
nsufficient to detect thin neointimal coverage after DES.
ngioscopy is a robust tool for the qualitative assessment
of neointimal coverage after
percutaneous coronary inter-
vention in patients (21–25).
Accordingly, we used angios-
copy for the assessment of thin
neointimal coverage after
sirolimus-eluting stent (SES)
implantation and IVUS for the
quantitative assessment of the
vessel characteristics in this
study to explore the determi-
nants of neointimal coverage
after SES implantation.
ethods
atients. We evaluated 54 consecutive stented coronary
rtery lesions in 29 patients who had undergone SES
mplantation for de novo lesions and agreed to receive
ngioscopy at follow-up catheterization between January
005 and December 2006. All patients received IVUS
valuation immediately after SES implantation. We ex-
luded 26 of the 54 SES lesions from analysis, because SES
ad been implanted at ostial location and/or overlapped on
ther stents. Consequently, the analysis included 28 SES
esions from 15 patients (14 men, mean age 60  11 years,
ge range 35 to 75 years). Hypertension included 1 or more
f the following: antihypertensive medication, systolic blood
ressure 140 mm Hg, diastolic blood pressure 90 mm
g. Hyperlipidemia included 1 or more of the following:
ipid-lowering medication, total cholesterol 220 mg/dl,
ow-density lipoprotein cholesterol 140 mg/dl, high-
bbreviations
nd Acronyms
MS  bare-metal stent(s)
SA  cross-sectional area
ES  drug-eluting stent(s)
EM  external elastic
embrane
VUS  intravascular
ltrasound
SA  minimum stent area
ES  sirolimus-eluting
tent(s)ensity lipoprotein cholesterol 40 mg/dl, or triglycerides s150 mg/dl. Diabetes mellitus included 1 or more of the
ollowing: antihyperglycemic medication or insulin treated,
bA1C 6.5%. The Ethics Committee at Kansai Rosai
ospital approved the study, and all patients gave written
nformed consent.
VUS imaging. Post-procedural IVUS examination was per-
ormed after intracoronary administration of 1 to 2 mg
sosorbide dinitrate with a commercially available IVUS
ystem, which incorporated a 40-MHz transducer with a
hort monorail imaging sheath (Boston Scientific Corpora-
ion, Natick, Massachusetts). The IVUS catheter was ad-
anced distal to the stented lesion, and imaging was per-
ormed retrograde until the aorto-ostial junction at the
utomatic pullback speed of 0.5 mm/s.
VUS analysis. Qualitative and quantitative analyses were
erformed, conforming to the criteria of the American
ollege of Cardiology clinical expert consensus document
n IVUS (26). With planimetry software (TapeMeasure,
NDEC Systems, Inc., Capitola, California), stented seg-
ents and proximal and distal references were analyzed to
btain external elastic membrane cross-sectional area (EEM
SA) (mm2), lumen CSA (mm2), and minimum stent CSA
MSA) (mm2). Plaque burden (%) was defined as (EEM
SA minus lumen CSA) divided by EEM CSA. The
roximal and distal reference segments were the least-
iseased image slices (largest lumen with least plaque)
ithin 5 mm proximal and distal to the lesion but within the
ame segment and before any major side branch. Degree of
he stent expansion was evaluated by 2 parameters: the ratio
f the MSA to the average reference lumen CSA (stent-
xpansion index); and the ratio of the MSA to the average
eference EEM CSA (stent-size index). Incomplete appo-
ition was defined as 1 or more stent struts clearly separated
rom the vessel wall with the evidence of blood speckles
ehind the strut, excluding overlapped side branches (27).
ngioscopic procedures. At follow-up, all stented segments
ere assessed with a 4.5-F rapid-exchange coronary angio-
cope (Vecmova, Clinical Supply Corp., Gifu, Japan), which
as compatible with a conventional 0.014-inch angioplasty
uidewire and an 8-F guiding catheter. The system and
rocedure have been described elsewhere (22). In brief, the
ptical fiber was advanced at the distal segment of the
oronary artery and was slowly pulled back from the distal
dge of the stent to the proximal edge under angioscopic
nd angiographic guidance. The images were recorded onto
digital video disc for offline analysis. Voice announcements
egarding the angiographic guidance were also recorded.
ngioscopic analysis. Angioscopic evaluation focused on
he neointimal coverage over the stent struts. Neointimal
overage was classified into 4 grades as previously described
23). In brief: grade 0  stent struts were fully visible,
imilar to immediately after implantation; grade 1  stent
truts bulged into the lumen and, although covered, were
till transparently visible; grade 2  stent struts were
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991mbedded by the neointima but were translucently seen; and
rade 3  stent struts were fully embedded and were
nvisible by angioscopy. Neointimal coverage was evaluated
n the entire stented segments, and if neointimal coverage
as heterogeneous, the dominant pattern was adopted. We
lassified 28 stented segments into 2 groups on the basis of
hether the stent struts were embedded by the neointima or
ot. Grade 0/1 was grouped as “incomplete” neointimal
overage, and grade 2/3 was grouped as “complete”
overage.
uantitative coronary angiography. Coronary angiography
as performed at least in 10 projections and was analyzed by
uantitative coronary angiography with the Cardiovascular
ngiography Analysis System (Pie Medical BV, Maas-
richt, the Netherlands). Minimal lumen diameter, refer-
nce diameter, and percent diameter stenosis before and
fter intervention were measured on the “worst view” (28).
tatistical analysis. Statistical analysis was performed with
tatView 5.0 (SAS Institute, Cary, North Carolina). Con-
inuous variables were expressed as mean  SD. Unpaired
tudent t test was used to compare 2 groups. Categorical
ariables were expressed as frequency and analyzed by chi
quare or Fisher exact test. A probability value of0.05 was
onsidered statistically significant.
esults
atients. Of the 15 patients analyzed, 14 (93%) presented
ultivessel diseases (53% had triple vessel disease), and 2
13%) had previous myocardial infarction. Ten patients had
ypertension (67%), 11 had hyperlipidemia (73%), 5 had
iabetes mellitus (33%), and 4 were current smokers (27%)
t the time of stent implantation.
ngioscopic ﬁndings. Angioscopic follow-up was per-
ormed 11  6 months after SES implantation. Among the
Table 1. Clinical Characteristics
Complete
Coverage
Incomplete
Coverage p Value
Segments 10 18
Age, yrs 63  7 60  14 0.5
Male 10 (100) 17 (94) 1.0
Prior MI 5 (50) 7 (39) 0.7
Risk factors
Hypertension* 8 (80) 12 (67) 0.7
Hyperlipidemia† 7 (70) 12 (67) 1.0
Diabetes mellitus‡ 4 (40) 3 (17) 0.2
Current smoker 3 (30) 5 (28) 1.0
Values are presented as n, mean  SD, or n (%). *Receiving antihypertensive medication or
systolic blood pressure140 mmHg or diastolic blood pressure90 mmHg; †total cholesterol
220 mg/dl or low-density lipoprotein cholesterol 180 mg/dl or high-density lipoprotein
cholesterol40 mg/dl or triglyceride 150 mg/dl or receiving lipid-lowering treatment; ‡oral-
agent or insulin treated or HbA1C6.5%.mMImyocardial infarction.8 SES-implanted lesions, angioscopic grades were distrib-
ted as: grade 0  0 (0%); grade 1  18 (64%); grade 2 
(29%); and grade 3  2 (7%). Hence, 10 lesions showed
omplete coverage (36%), and 18 showed incomplete
overage.
linical and procedural characteristics. Clinical and proce-
ural characteristics are listed in Tables 1 and 2. There were no
ifferences in follow-up duration (10  5 months vs. 11  7
onths, p 0.8), stent diameter (3.2 0.4 mm vs. 3.0 0.4
m, p  0.2), stent length (23  4 mm vs. 24  5 mm, p 
.6) between the complete and the incomplete coverage
roups.
ngiographic measurements. There were no significant dif-
erences in pre-procedural angiographic findings between
he complete coverage and the incomplete coverage groups:
eference diameter (2.9  0.5 mm vs. 2.7  0.4 mm, p 
.2), minimal lumen diameter (0.6  0.3 mm vs. 0.6  0.3
m, p  0.4), lesion length (14  10 mm vs. 16  6 mm,
 0.7), and percent diameter stenosis (79  9% vs. 79 
0%, p  1.0). Post-procedural minimal lumen diameter
2.6  0.9 mm vs. 2.4  0.2 mm, p  0.4), and percent
iameter stenosis (16  13% vs. 15  6%, p  0.7) were
lso similar between the groups.
VUS ﬁndings. The post-procedural IVUS findings are
hown in Table 3. Incomplete stent apposition was revealed
n 3 segments (30%) in complete coverage and in 4 (22%)
egments in incomplete coverage (p  0.7).
iscussion
he present study demonstrated that a higher ratio of the
tent area to the vessel area (i.e., “optimal stent sizing”)
ight contribute to the angioscopically complete neointimal
overage after SES implantation. This was in accordance
ith the earlier angioscopic (22,29) and IVUS observations
n BMS (30). Histopathological studies also demonstrated
he effect of overexpansion on the neointimal proliferation
n animal models (31,32). Farb et al. investigated the
istology of 55 stents in human coronary vessels and found
hat neointimal thickness was significantly greater when
Table 2. Lesion and Procedural Characteristics
Complete
Coverage
Incomplete
Coverage p Value
Vessels (LAD/LCX/RCA) 3/5/2 10/4/4 0.3
Location (proximal/middle/d) 8/2/0 1/9/8 0.2
Direct stenting 6 (60) 5 (28) 0.1
After dilation 2 (20) 8 (44) 0.2
Maximum balloon inﬂation, atm 15  4 16  3 0.9
Maximum balloon diameter, mm 3.3  0.4 3.3  0.3 0.8
Values are presented as n, n (%), or mean SD.
LAD left anterior descendingartery; LCX left circumflexartery; RCA right coronary artery;
Prox. proximal; Mid.middle.edial damage was present at the strut site than when the
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992truts were in contact with the intact media (33). They also
ound that medial damage and stent over-sizing relative to
he reference arterial lumen were associated with increased
eointimal growth. Because vessel injury associated with
verstretching might lead to surplus neointimal prolifera-
ion (34,35), it is not surprising to see less extent of
eointimal hyperplasia in the lesions with stent under-
izing. In this study, large MSA and large lumen CSA at
istal reference site were also identified as univariate pre-
ictors for complete neointimal coverage. Although smaller
nal stent area has been reported as a predictor of in-stent
estenosis after BMS implantation (36,37), it does not
onflict with our results. Earlier IVUS studies reported a
ositive correlation between the stent area and the neointi-
al area (38,39). Hoffmann et al. (30) have reported
ontribution of aggressiveness of the stent implantation
echnique to tissue proliferation inside the stent. Large stent
rea abolished the impact of neointimal hyperplasia in terms
f restenosis. Hence, “the bigger, the better” theory has been
ccepted to prevent clinical restenosis after BMS implanta-
ions. In the present study, large lumen CSA at the
eference site was also associated with complete neointimal
overage, and IVUS showed no difference in EEM CSA
etween the groups. Thus, neointimal coverage was not
ecessarily attenuated in small vessels but was attenuated in
he vessels that were diffusely diseased with large plaque
urden. Surprisingly, these univariate predictors coincided
ith the recent IVUS study that demonstrated IVUS
redictors for DES thrombosis included small minimum
tent area and large residual disease at the stent edges (16).
Although an IVUS study revealed the high prevalence of
ncomplete stent apposition in patients with stent throm-
osis (40), the impact of incomplete stent apposition on
linical events has still been controversial (41,42). In our
tudy population, 22 of the 28 lesions underwent follow-up
Table 3. IVUS Parameters
Complete
Coverage
Incomplete
Coverage p Value
Proximal reference EEM CSA, mm2 16.3 2.6 17.4 4.4 0.5
Proximal reference lumen CSA, mm2 8.6 2.0 8.8 3.9 0.8
Proximal reference plaque burden, % 47 14 51 12 0.4
Distal reference EEM CSA, mm2 10.7 3.4 9.4 2.4 0.3
Distal reference lumen CSA, mm2 6.1 1.4 4.9 1.2 0.02
Distal reference plaque burden, % 40 13 47 8 0.06
Minimum stent CSA, mm2 7.0 1.8 5.3 1.9 0.02
Stent-size index* 0.52 0.11 0.39 0.09 0.002
Stent-expansion index† 0.95 0.18 0.80 0.22 0.08
Values are presented as mean SD. *Stent-size index was defined as the ratio of the minimum
stent area to the average reference external elasticmembrane (EEM) cross-sectional area (CSA);
†stent-expansion index was defined as the ratio of the minimum stent area to the average
reference lumen CSA.
IVUS intravascular ultrasound.VUS. Follow-up IVUS revealed incomplete stent apposi- rion in 11 lesions (3 lesions, 50%, in complete coverage; 8
esions, 50%, in incomplete coverage, p  1.0). There were
o significant differences with regard to the stent malappo-
ition and neointimal coverage by follow-up IVUS in our
tudy population.
linical implications. Earlier studies have shown that in-
omplete neointimal coverage within the stents has a trend
oward thrombus formation with/without clinical presenta-
ion (15,17,23,24). In addition, several experimental models
evealed incomplete re-endothelialization associated with
hrombosis in irradiated vessels (18,20). Significant suppres-
ion of neointimal formation is considered as a cause of late
hrombosis after vascular brachytherapy. In fact, re-stenting
nto irradiated segment increased the frequency of stent
hrombosis (43,44). A pathological study revealed fatal late
oronary stent thrombosis cases had incomplete neointimal
ealing over the stent (11). A recent pathological study of
ate DES thrombosis also demonstrated that incomplete
eointimal coverage of stent struts was the most important
orphometric predictor of late stent thrombosis (17). A
revious IVUS study also disclosed that stent under-
xpansion was related to SES thrombosis (45). In the
resent study, the stented segments with smaller stent area
elative to the vessel size were more prone to incomplete
eointimal formation after stenting than those with larger
tent area. Thus, it is reasonable to speculate that stent
mplantation with under-expansion that caused stent
hrombosis has incomplete neointimal coverage.
An IVUS study showed that SES had a lower optimal
SA threshold (5.0 mm2) compared with BMS (6.5 mm2)
o predict adequate follow-up patency (46). Although ag-
ressive stent expansion might be unnecessary with SES for
he prevention of restenosis, the present results indicate that
dequate stent area relative to the vessel area might still be
mportant to prevent thrombosis by adequate neointimal
ormation. Recently, IVUS guidance at the time of DES
mplantation has been reported to be an independent
redictor of freedom from stent thrombosis (47). The vessel
ize (i.e., EEM CSA) as well as the plaque distribution
annot be estimated with angiography but needs IVUS
uidance. Considering the advantage of IVUS guidance
ver angiographic guidance, we evaluated degree of stent
xpansion not only by using “stent-expansion index” (MSA/
verage reference lumen CSA) but by using “stent-size
ndex” (MSA/average reference EEM CSA). Although
oth angiographic measurements and stent-expansion index
ere similar between the complete and the incomplete
overage groups in the present study, IVUS evaluation
isclosed the significant difference in stent-size index be-
ween the groups. With IVUS guidance, the adequate stent
iameter and length can be selected, and stent expansion
an be controlled safely in accordance with the vessel size.
aken together, IVUS-guided adequate stent expansionelative to the vessel size might be important to avoid not
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993nly stent restenosis but also stent thrombosis after SES
mplantation.
tudy limitations. This study was a single-center, nonran-
omized, retrospective study with a small sample size.
onetheless, this study was the first to explore the contrib-
tors to neointimal coverage after SES implantation with
oth angioscopy and IVUS. Pre-procedural and follow-up
VUS were not consistently performed in this study. Variety
f tissue characteristics at the target lesion, such as lipid pool
nd calcification, might have affected the stent expansion as
ell as the subsequent neointimal proliferation. However,
n earlier IVUS study showed that pre-procedural IVUS
ndings were not related to stent expansion (48). Further
ystematic investigation should be required to clarify the
elationships of the pre-procedural tissue characteristics,
tent expansion, and neointimal proliferation. This study
nly investigated neointimal morphology; local endothelial
unctions remain unclear.
onclusions
dequate stent sizing with IVUS relative to the vessel size
ight contribute to the complete neointimal coverage after
ES implantation.
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